Molecules Concept of neurons and nervous system


connecticut biotech company

We develop a nanotechnology-based diagnostic kit for the early detection of neurodegenerative diseases, such as Alzheimer’s Disease

About Us

CrystalNeuro LLC is a biotech company, established in 2020 in Connecticut. The core business is a nanotechnology-based diagnostic kit for the early detection of neurodegenerative diseases (NDDs), such as Alzheimer’s Disease (AD). A patent for the technology is filed to the USPTO in Dec. 2021.

Problem and Market Pain

There are currently no objective diagnostics for early detection of NDDs and AD. Existing ones are invasive, expensive, and only effective at advanced stages (a large number of brain cells are damaged). However, the numbers of population impacted by AD rise a significant need in screening test to be associated with physical exam.


Diagnostic kit for early detection of AD, as a screening test applicable for patients 45-55 yrs, focused on identifying key biomarkers of AD through labeling with a proprietary use of nanomaterial.

Technology: Nanoparticle-based detection and treatment platforms to recognize an early biomarker of AD and track it in the brain and cerebrospinal fluid which surpasses traditional.

What We Offer

CrystalNeuro is developing a biomarker test kit to be used at annual physical exam that will allow early detection of changes in human brain and cerebrospinal liquid leading to development of Alzheimer’s disease and other types of dementia. Our test kit is based on the use of nanomaterial with special properties. It will allow biomarker detection about 20 years prior statistically established age of symptoms appearance. [could appear early or later but statistics bis brining to this average age] After the biomarker is detected, nanotechnology will be used to minimize its effects on a body on molecular level. The same nanomaterial will be used for the development of targeted delivery of treatment to specific region.

CrystalNeuro is considering two modes of biomarker detection – endomicroscopy and photoacoustic.

Our Team

Ludmila I. Kvochina, MD, Ph.D.

To accomplish the goal, Dr. Ludmila I. Kvochina, MD, Ph.D. – project PI, 10 years in Neuroscience, working with biomarkers involvement to neuroplasticity processes, 8 years in commercial companies, built R&D lab complex for a biotech startup, I-Corp, MIT (NSF funded), and Accelerator for Biosciences in Connecticut (ABCT) graduate, is collaborating with a diverse team of scientists, engineers, academics, business, and financial advisors combined together their efforts; colleagues include a diverse fusion of backgrounds and cultures for the success. We all share a common goal and passion to make an impact.


CrystalNeuro Collaborators

Xiulng Lu, PhD

University of Connecticut, Professor of Pharmaceutics

Xiuling is mastering the task of nanomaterial-biomolecule conjugation.

Rebecca L. Cunningham, PhD

North Texas University, Professor of Pharmaceutical Sciences

Rebecca is a subcontractor, and lead, and performs animal and brain slices study for the project, including methods/ protocols modeling.

Our Advisors

Thomas Conningham, PhD

North Texas University, School of Biomedical Sciences, Regents Professor and Associate Vice President, Associate Vice President of Research

Kathleen Adams

University of Connecticut, Technology Commercialization Services

University of Connecticut, Technology Commercialization Services

Tom Gerson

Our Additional Services

Research and development in bio-technology/ pharmaceutical field

Consulting in life science field

Bio -medical/medical/scientific translation and interpreting

Let's work together




62 Brownson Dr., Shelton, CT, 06484